UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database

Expert opinion on drug safety, 2023-11, p.1-7

2023

Link zum Volltext

Verfügbarkeit prüfen

Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Expert opinion on drug safety, 2024-04, p.1-7

2024

Link zum Volltext

Verfügbarkeit prüfen

Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system

Expert opinion on drug safety, 2023-10, Vol.22 (10), p.943-955

2023

Link zum Volltext

Verfügbarkeit prüfen

Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)

Schizophrenia research, 2023-06

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database

Seizure (London, England), 2024-04, Vol.117, p.253-260

2024

Link zum Volltext

Verfügbarkeit prüfen

Pneumatosis intestinalis associated with α-glucosidase inhibitors: a pharmacovigilance study of the FDA adverse event reporting system from 2004 to 2022

Expert opinion on drug safety, 2023-11, p.1-10

2023

Link zum Volltext

Verfügbarkeit prüfen

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Frontiers in pharmacology, 2022-04, Vol.13, p.849758-849758

2022

Link zum Volltext

Verfügbarkeit prüfen

Case–non-case studies: Principle, methods, bias and interpretation

Therapie, 2019-04, Vol.74 (2), p.225-232

Faillie, Jean-Luc

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case/non-case analysis

Therapie, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study

International immunopharmacology, 2024-04, Vol.133, p.112022-112022, Article 112022

2024

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system

Frontiers in pharmacology, 2022-11, Vol.13, p.1075966-1075966

2022

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular toxicity induced by SSRIs: Analysis of spontaneous reports submitted to FAERS

Psychiatry research, 2023-08, Vol.326, p.115300-115300, Article 115300

2023

Link zum Volltext

Verfügbarkeit prüfen

PD-1/PD-L1 inhibitors associated hypophysitis: An analysis from the FAERS database and case reports

Drug Discoveries & Therapeutics, 2024, pp.2023.01092

2024

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity and specificity in signal detection with the reporting odds ratio and the information component

Pharmacoepidemiology and drug safety, 2023-08, Vol.32 (8), p.910-917

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of temozolomide with progressive multifocal leukoencephalopathy: a disproportionality analysis integrated with network pharmacology

Expert opinion on drug safety, 2023-11, p.1-10

2023

Link zum Volltext

Verfügbarkeit prüfen

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib

Heliyon, 2024-03, Vol.10 (6), p.e27529-e27529, Article e27529

2024

Link zum Volltext

Verfügbarkeit prüfen

Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases

Journal of clinical epidemiology, 2021-06, Vol.134, p.14-21

2021

Link zum Volltext

Verfügbarkeit prüfen

Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source

Briefings in bioinformatics, 2021-11, Vol.22 (6)

2021

Link zum Volltext

Verfügbarkeit prüfen

Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System

British journal of clinical pharmacology, 2022-09, Vol.88 (9), p.4180-4190

2022

Link zum Volltext

Verfügbarkeit prüfen

Drug-induced hyperglycemia and diabetes

Therapie, 2024-03, Vol.79 (2), p.221-238

2024

Link zum Volltext

Verfügbarkeit prüfen

Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study

European heart journal, 2021-10, Vol.42 (38), p.3915-3928

2021

Link zum Volltext

Verfügbarkeit prüfen

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

British journal of clinical pharmacology, 2011-12, Vol.72 (6), p.905-908

2011

Link zum Volltext

Verfügbarkeit prüfen

Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database

Expert opinion on drug safety, 2023-12, p.1-7

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database

Expert opinion on drug safety, 2023-12, p.1-12

2023

Link zum Volltext

Verfügbarkeit prüfen

Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system

Expert opinion on drug safety, 2023-10, Vol.ahead-of-print (ahead-of-print), p.1-13

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 310

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(291)
Mit Volltextzugriff
(251)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(207)
Life Sciences & Biomedicine
(198)
Disproportionality Analysis
(192)
Pharmacovigilance
(130)
Pharmacology & Pharmacy
(124)
Humans
(114)
Disproportionality
(71)
Social Sciences
(66)
Adverse Drug Reaction Reporting Systems
(41)
Pharmacology
(40)
Female
(39)
Faers
(38)
Male
(36)
Databases, Factual
(34)
Disproportionate Representation
(33)
Drugs
(31)
United States
(31)
Adverse Events
(30)
Signal Detection
(29)
Statistical Analysis
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(21)
... seit 30 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database

Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system

Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)

Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database

Pneumatosis intestinalis associated with α-glucosidase inhibitors: a pharmacovigilance study of the FDA adverse event reporting system from 2004 to 2022

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Case–non-case studies: Principle, methods, bias and interpretation

Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case/non-case analysis

Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system

Cardiovascular toxicity induced by SSRIs: Analysis of spontaneous reports submitted to FAERS

PD-1/PD-L1 inhibitors associated hypophysitis: An analysis from the FAERS database and case reports

Sensitivity and specificity in signal detection with the reporting odds ratio and the information component

Association of temozolomide with progressive multifocal leukoencephalopathy: a disproportionality analysis integrated with network pharmacology

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib

Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases

Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source

Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System

Drug-induced hyperglycemia and diabetes

Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database

Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database

Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system

Suchergebnisse filtern